Compass Therapeutics, Inc.CMPXNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+54.7%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+54.7%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
8.9x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 100.00% |
| Q3 2025 | 24.92% |
| Q2 2025 | -17.25% |
| Q1 2025 | -8.40% |
| Q4 2024 | -35.42% |
| Q3 2024 | 18.65% |
| Q2 2024 | -17.82% |
| Q1 2024 | 17.04% |
| Q4 2023 | -29.07% |
| Q3 2023 | 10.58% |
| Q2 2023 | -37.34% |
| Q1 2023 | 24.65% |
| Q4 2022 | -2.30% |
| Q3 2022 | -40.18% |
| Q2 2022 | -25.13% |
| Q1 2022 | 44.76% |
| Q4 2021 | -122.09% |
| Q3 2021 | 89.49% |
| Q2 2021 | -658.81% |
| Q1 2021 | 7.69% |
| Q4 2020 | 11.28% |
| Q3 2020 | -76.75% |
| Q2 2020 | 13.05% |
| Q1 2020 | 8.92% |
| Q4 2019 | 23.63% |
| Q3 2019 | 3.34% |
| Q2 2019 | 18.13% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |